Abbott Laboratories stock holds near $108 after strong Q2
📈 Abbott Laboratories reported Q2 revenue of $12.59 billion, marking a 13.0 percent increase from the prior year.
💰 The company delivered adjusted EPS of $1.31, beating analyst consensus estimates by $0.03.
🎯 Management raised full-year fiscal 2026 EPS guidance to a range of $5.45 to $5.60.
📊 Net margin for the quarter stood at 11.65 percent with a return on equity of 17.69 percent.
💵 Free cash flow for Q1 2026 was reported at $916.0 million, down 1.8 percent year-over-year.
📉 Stock price traded near $108.29, trading below the consensus analyst target of $119.50.
🏥 Business segments include diagnostics, medical devices, nutrition, and established pharmaceuticals.
📅 Q3 2026 EPS guidance is set between $1.38 and $1.46 per share.
Bullish Signals
- Abbott Laboratories beat Q2 consensus EPS estimates by $0.03, delivering $1.31 adjusted earnings versus the expected $1.28.
- The company achieved a 13.0 percent year-over-year revenue growth, reaching $12.59 billion in total revenue for the quarter.
- Management provided strong full-year fiscal 2026 guidance with EPS projected between $5.45 and $5.60.
- Abbott maintained healthy profitability metrics with a net margin of 11.65 percent and a return on equity of 17.69 percent.
- Analyst consensus target price of $119.50 implies approximately 10.4 percent upside from the current trading price.
Risk Factors
- Free cash flow for Q1 2026 declined by 1.8 percent year-over-year to $916.0 million.
- Shares traded below their 52-week high range, indicating some near-term price weakness relative to recent peaks.
Full Analysis
Abbott Laboratories reported a strong second quarter ended July 16, 2026, with revenue reaching $12.59 billion, representing a 13.0 percent year-over-year increase. The company delivered adjusted earnings per share of $1.31, which beat the consensus estimate of $1.28 by $0.03. This performance was driven by its diversified product mix spanning diagnostics, medical devices, nutrition, and established pharmaceuticals.
Following the quarterly results, management provided forward guidance for the third quarter of 2026 with EPS expected between $1.38 and $1.46, and full-year fiscal 2026 EPS guidance ranging from $5.45 to $5.60. The company maintained a net margin of 11.65 percent and a return on equity of 17.69 percent during the period. Analysts maintain a consensus target price of $119.50, suggesting potential upside for the stock currently trading near $108.
Financial metrics indicate robust operational health with free cash flow reported at $916.0 million in the first quarter of 2026, though this figure saw a slight decline of 1.8 percent compared to the same quarter a year prior. The market capitalization stands at approximately $187.38 billion as of September 4, 2026, with shares trading below their 52-week high and the consensus analyst target price.
